07:53 AM EDT, 09/25/2025 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said Thursday it is offering its Sotyktu and Eliquis drugs to eligible US patients at "steeply discounted prices" in an expansion of its direct-to-patient offerings.

Sotyktu, the company's drug treating moderate-to-severe plaque psoriasis, will be offered through its new BMS Patient Connect platform at an over 80% discount to the current list price starting January 2026, Bristol-Myers said.

The Bristol-Myers Squibb-Pfizer (PFE) Alliance program for Eliquis, a treatment for venous thromboembolism, was launched earlier in September, with a discount of over 40% to the list price offered to cash-paying patients, the company said.

The move comes around two months after President Donald Trump sent letters to global drug manufacturers demanding that they price new medicines in the US similar to how they charge other wealthy nations and set up direct-to-consumer channels to sell some popular treatments at a discount, according to a Bloomberg News report Thursday.